BioSpace News Archive

The Arizona Bioindustry Association (AZBio) today announced that Regenesis Biomedical, Inc. has been named the Arizona Bioscience Company of the Year and will be honored on October 2, 2019, at the AZBio Awards.

At the 18th Human Proteome Organization World Congress, Bruker announced the release of the diaPASEF workflow, a novel data-independent acquisition method on the timsTOF Pro platform.

Accuray Incorporated announced that, on September 11, 2019, China’s Customs Tariff Commission of the State Council issued a tariff exemption for medical linear accelerators.

CASI Pharmaceuticals, Inc. announces that the Chinese National Medical Product Administration, the Chinese FDA, has accepted the clinical trial application for CNCT19 for investigation in relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

The Next Generation Of This Pioneering Meniscal Repair Technology

Firefly Health, a technology-powered concierge medicine service for average Americans, announced it has closed $10.2 million in a Series A funding round.

Glenmark Pharmaceuticals (Glenmark), a research-led, integrated global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma who have received prior therapies.

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that two independent review committees completed their planned safety and efficacy assessment of data from 50% of the planned study population enrolled in the Company’s Phase 2 open-label clinical trial of fosmanogepix (APX001) for the treatment of candidemia.

DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that the first 30 subjects have been safely treated its first-in-human U.S. clinical study of IDCT, an allogeneic, injectable disc cell therapy for mild to moderate degenerative disc disease (DDD

Bayer today announced Daniella Foster as the new Head of Public Affairs and Sustainability for the Consumer Health Division, effective September 16.